Luigi Stasi

Shanghai Zhangjiang Laboratory — China

Materials Science · Physical Sciences

14h-index548citations47works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Crystallization and Solubility Studies(10), X-ray Diffraction in Crystallography(10), Synthesis and Biological Evaluation(6), Inflammatory mediators and NSAID effects(5), Parkinson's Disease Mechanisms and Treatments(4)

Publications47 total

Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitors
RSC Medicinal Chemistry·2025Open Access
Design of Novel Series of Antimalarial PMX Inhibitors with Increased Half-Life via Molecular Property Optimization
ACS Medicinal Chemistry Letters·2023· 5 citedOpen Access
Abstract 5555: <i>In vivo</i> and <i>in vitro</i> characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist
Cancer Research·2020· 2 cited
Abstract 4983: Discovery and characterization of next-generation small molecule direct STING agonists
Immunology·2019· 1 cited
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy
Bioorganic & Medicinal Chemistry Letters·2018· 14 citedOpen Access
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors
Bioorganic & Medicinal Chemistry Letters·2018· 19 citedOpen Access
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Bioorganic & Medicinal Chemistry Letters·2017· 22 citedOpen Access
A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease Using RapidFire Mass Spectrometry
SLAS DISCOVERY·2015· 36 citedOpen Access
Prostaglandin EP<sub>4</sub>Antagonists
Pharmaceutical Patent Analyst·2013· 9 cited
Prostaglandin EP4 antagonists.
PubMed·2013
Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2013· 11 citedOpen Access
CCDC 817661: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817651: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817659: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817658: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817660: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817652: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
CCDC 817653: Experimental Crystal Structure Determination
The Cambridge Structural Database·2013Open Access
SAT0074 Selectively antagonizing the EP4 prostanoid receptor significantly ameliorates pathological features in a rat model for inflammatory arthritis
Annals of the Rheumatic Diseases·2012
ChemInform Abstract: Synthesis, Pharmacophore Modeling and in vitro Activity of 10,11‐Dihydrodibenzo[b,f]oxepine‐4‐carboxamide Derivatives as Novel and Potent Antagonists of the Prostaglandin EP<sub>4</sub> Receptor.
ChemInform·2012
page 1 of 3Next →

Frequent Co-authors

Antonio Giordani(13), Andrea Cappelli(12), Salvatore Valenti(12), Salvatore Vomero(12), Germano Giuliani(9), Gianfranco Caselli(9), Maurizio Botta(9), M. Anzini(9), G. Bini(8), Carla Ghelardini(8), Lorenzo Di Cesare Mannelli(8), Alessandra Concas(8), Patrizia Porcu(8), Gianluca Giorgi(7), Raffaele Saladino(7), Rosario Nicoletti(7), Marco Paolino(7), G. Biggio(7), Francesco Makovec(6), Manuela Borriello(6)